Skip to main navigation Skip to search Skip to main content

Pharmacological ascorbic acid suppresses syngeneic tumor growth and metastases in hormone-refractory prostate cancer

Research output: Contribution to journalArticlepeer-review

68 Scopus citations

Abstract

Aim: The aim of this study was to test for the influence of ascorbic acid on tumorigenicity and metastases of implanted PAIII prostate cancer adenocarcinoma cells in syngeneic LW rats. Materials and Methods: Hormone-refractory prostate cancer PAIII cells were implanted subcutaneously into immunologically intact, Lobund-Wistar (LW) rats. Intraperitoneal pharmacological doses of ascorbic acid were administered each day for the ensuing 30 days. On the 40th day, animals were sacrificed. Local tumor weights were measured, and metastases were counted. Results: At the end of the 40 day experimental period, the primary tumors were found to be significantly reduced in weight (p=0.026). In addition, sub-pleural lung metastases were even more profoundly reduced in number and size (p=0.009). Grossly enlarged ipsilateral lymph node metastases declined from 7 of 15 rats to 1 of 15 rats. Conclusion: Pharmacological doses of ascorbic acid suppress tumor growth and metastases in hormone-refractory prostate cancer.

Original languageEnglish
Pages (from-to)249-255
Number of pages7
JournalIn Vivo
Volume24
Issue number3
StatePublished - 2010

Keywords

  • Ascorbic acid
  • Metastases
  • Prostate
  • Syngeneic
  • Tumor

Fingerprint

Dive into the research topics of 'Pharmacological ascorbic acid suppresses syngeneic tumor growth and metastases in hormone-refractory prostate cancer'. Together they form a unique fingerprint.

Cite this